Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet Haematology

Core Insights - Pharvaris has published results from two Phase 2 clinical studies, CHAPTER-1 and RAPIDe-1, demonstrating the efficacy and safety of deucrictibant, a bradykinin B2 receptor antagonist, for managing hereditary angioedema (HAE) [1][2] Study Results - CHAPTER-1 study showed a statistically significant reduction in the occurrence of HAE attacks and improvements in disease control and health-related quality of life, with deucrictibant being well tolerated at both tested doses [3] - RAPIDe-1 study indicated a statistically significant reduction in the severity of HAE attack manifestations, along with reduced time to symptom relief and resolution, with deucrictibant well tolerated at all tested doses [4] Product Development - Deucrictibant is being developed in two formulations: an extended-release tablet for prophylactic treatment and an immediate-release capsule for on-demand treatment, aiming to provide a comprehensive approach to HAE management [8] - The company is preparing marketing authorization applications for the immediate-release capsule and is conducting a Phase 3 study (CHAPTER-3) for the extended-release tablet, with topline data expected in Q3 2026 [9] Industry Context - The use of bradykinin B2 receptor antagonism has been established as the standard-of-care for on-demand treatment of HAE attacks, with deucrictibant emerging as a potentially unique oral therapy for both prophylactic and acute treatment [5][2] - The concurrent publication of the study results in The Lancet Haematology adds to the scientific evidence supporting the management of bradykinin-mediated angioedema [5]